Wellbeing Digital Sciences Inc. - KONEF STOCK NEWS

KetamineOne Capital Limited (OTC: KONEF) is launching two significant research studies focusing on treatment-resistant depression and post-traumatic stress disorder (PTSD) across its North American clinics. The PTSD Study, lasting twelve weeks, aims to assess the effectiveness of a physical therapy program for veterans and first responders, while the Depression Study will investigate the efficacy of IV ketamine therapy. Both studies are expected to begin in November 2021 and will utilize objective biometric data to improve treatment outcomes.

KetamineOne Capital Limited (OTC: KONEF) has announced its contract research organization, KGK Science Inc., will develop a protocol for a ketamine clinical trial in Miami, Florida. This trial aims to gather objective data on how intravenous ketamine treatments may foster neuroplasticity and alleviate depression, with or without PTSD. Patients will receive four ketamine infusions, with measurements taken before, during, and after treatment. This initiative aligns with the company’s goal of becoming a leader in mental health treatments across North America.

KetamineOne Capital Limited has retained Integral Wealth Securities Limited as a market-maker to enhance share liquidity and stabilize the market for its stock (KONEF). The agreement includes an initial payment of $6,000 monthly for three months and aims to rectify supply and demand imbalances. Ketamine One operates 16 clinics across North America, focusing on mental health treatments, and is consolidating the fragmented industry. The company emphasizes its commitment to providing accessible mental health therapy.

KetamineOne Capital Limited (OTC: KONEF) has announced a non-binding letter of interest with Veteran Services USA to lease 5,000 square feet for a therapy center in Blue Island, Illinois. This center aims to provide ketamine-assisted therapy to veterans dealing with PTSD. The initiative seeks to enhance mental health treatment using innovative therapies. Additionally, Ketamine One is evaluating more clinic acquisitions across the U.S. Following this, the company terminated a previous letter of intent with Illumma LLC.

Ketamine One Capital Limited has partnered with Psychology & Counselling Services Group (PCSG) to enhance mental health services through its subsidiary, IRP Health Ltd.. Starting October 2021, PCSG will offer a range of psychological and therapeutic services, aiming to address the mental health needs of veterans, first responders, and others. With over 35 professionals and extensive experience, PCSG has treated over 11,000 patients. This collaboration supports Ketamine One's mission to be a leader in North American mental health treatment and expands its service offerings across Ontario.

KetamineOne Capital Limited has entered into a non-binding letter of intent for an arrangement with Illumma LLC, enhancing its network of clinics in the U.S. The deal, valued at approximately $980,000, involves $490,000 in shares and $490,000 in cash, contributing $350,000 to new clinic construction. The partnership aims to expand access to innovative ketamine therapies for mental health treatment, positioning Ketamine One as a leader in the industry and potentially attracting further partnerships.

Ketamine One Capital Limited (KONEF) has signed an agreement with Cognetivity Neurosciences Ltd. to integrate Cognetivity’s Integrated Cognitive Assessment (ICA) into its North American clinics. This deployment aims to enhance cognitive monitoring for patients suffering from treatment-resistant depression and PTSD. The ICA is a rapid, user-friendly computer-based tool, set to improve ongoing treatment assessments. Additionally, both companies aim to collaborate on developing advanced mental health assessment tools. The mental health treatment market presents a substantial opportunity, estimated at US$238 billion.

KetamineOne Capital Limited has rebranded its subsidiary, Integrated Rehab and Performance Ltd., to IRP Health to reflect its evolution into a multidisciplinary business. The company is expanding with four new clinics in veteran-centric areas: Comox Valley, Ottawa, Halifax, and Surrey, with openings set from September to December 2021. The clinics are poised to address rising mental and physical health needs in Canada’s first responder and veteran communities, having already conducted over 10,000 treatments for these populations.

KetamineOne Capital Limited (KONEF) announced the formation of a new Medical Advisory Board (MAB) to enhance its mental health platform. Chaired by Dr. Mark Kimmins, the MAB includes renowned experts like Dr. Ravi Bains and Dr. Glen Brooks. This strategic move aims to position Ketamine One as a leader in psychedelic-assisted mental health treatments across North America. The company has allocated stock options for the advisors, emphasizing its commitment to developing innovative therapies.